Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 27, Issue 7, 2014, Pages 670-677

  Meng, Y Q ^a   Cao, X ^a   Wen, Z S ^a   Liu, Q W ^a   Tan, Z H ^a   Duan, H ^a   Ma, G W ^a   Lin, P ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Acute phase protein; Esophageal squamous cell carcinoma; Inflammation; Prognostic factor

Indexed keywords

C REACTIVE PROTEIN; SERUM AMYLOID A; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PREOPERATIVE PERIOD; PROGNOSIS; STATISTICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; SERUM AMYLOID A PROTEIN; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84906792063     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12128     Document Type: Article

References (34)

1. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer 2002; 102: 271-274.
3. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252.
4. Daly J M, Fry W A, Little A G etal. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000; 190: 562-572; discussion 572-3.
5. Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer-the advent of the era of individualization. N Engl J Med 2002; 347: 1705-1709.
6. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010; 10 (1): 2-3.
7. Coussens L M, Werb Z. Inflammation and cancer. Nature 2002; 420 (6917): 860-867.
8. Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
9. Sandler R S, Halabi S, Baron J A etal. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
10. Baron J A, Cole B F, Sandler R S etal. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
11. Harris R E, Chlebowski R T, Jackson R D etal. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101.
12. Schultz D R, Arnold P I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990; 20: 129-147.
13. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
14. McArdle P A, Mir K, Almushatat A S, Wallace A M, Underwood M A, McMillan D C. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127-129.
15. Tsilidis K K, Branchini C, Guallar E, Helzsouer K J, Erlinger T P, Platz E A. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008; 123: 1133-1140.
16. Scott H R, McMillan D C, Forrest L M, Brown D J F, McArdle C S, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002; 87: 264-267.
17. Pierce B L, Neuhouser M L, Wener M H etal. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 2009; 114 (1): 155-167.
18. Yokoi K, Shih L C, Kobayashi R etal. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 2005; 27: 1361-1369.
19. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson G G. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 2010; 14: 462-469.
20. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M etal. Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). J Clin Lab Anal 2012; 26: 73-81.
21. Guillem P, Triboulet J P. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005; 18: 146-150.
22. Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett 2003; 192 (1): 89-95.
23. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
24. Wang J Y, Zheng Y Z, Yang J etal. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer 2012; 12: 365.
25. Rice T W, Blackstone E H, Rusch V W. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
26. Fenton J J, Taplin S H, Carney P A etal. Influence of computer-aided detection on performance of screening mammography. N Engl J Med 2007; 356: 1399-1409.
27. Maury C P. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci (Lond) 1985; 68: 233-238.
28. Marhaug G, Hårklau L, Olsen B, Husby G, Husebekk A, Wang H. Serum amyloid A protein in acute myocardial infarction. Acta Med Scand 1986; 220: 303-306.
29. Grund B, Sabin C. Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Curr Opin HIV AIDS 2010; 5: 473-479.
30. Wang C Y, Hsieh M J, Chiu Y C etal. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 2009; 92: 270-275.
31. Preciado-Patt L, Levartowsky D, Prass M, Hershkoviz R, Lider O, Fridkin M. Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. Eur J Biochem 1994; 223 (1): 35-42.
32. Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O. Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol 1996; 156: 1189-1195.
33. Urieli-Shoval S, Shubinsky G, Linke R P, Fridkin M, Tabi I, Matzner Y. Adhesion of human platelets to serum amyloid A. Blood 2002; 99: 1224-1229.
34. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010; 42: 161-170.